文献速递浆细胞疾病造血干细胞移植与细胞治疗

复发或难治性多发性骨髓瘤标准治疗接受伊达基奥仑赛后早期血细胞减少与感染

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2022-01-01

这项多中心回顾性研究纳入52例接受标准治疗伊达基奥仑赛的复发/难治性多发性骨髓瘤患者,47例完成第90天随访。第30天65%、第90天40%患者存在≥3级血细胞减少;感染发生率54%,其中23%为≥3级。早期感染以细菌性(68%)和严重(50%)为主。

要点

  • 第30天65%、第90天40%患者存在≥3级血细胞减少。
  • 感染发生率54%,≥3级感染占23%。
  • 早期感染以细菌性(68%)和严重(50%)为主,后期仅13%为≥3级。

核心结论

  • 标准治疗接受伊达基奥仑赛后100天内≥3级血细胞减少和感染常见,需关注早期严重细菌感染。
  • 高骨髓瘤负荷、循环浆细胞及预处理前≥3级贫血与第30天和第90天≥3级血细胞减少相关;距末次桥接治疗至预处理时间较长是感染的唯一显著危险因素。

研究设计与样本

  • 多中心回顾性研究,纳入52例接受标准治疗伊达基奥仑赛的复发/难治性多发性骨髓瘤患者,47例完成第90天随访,数据在第100天删失。

主要发现

  • 第30天65%、第90天40%患者存在≥3级血细胞减少。
  • 88%患者使用粒细胞集落刺激因子,63%接受浓缩红细胞输注,42%接受血小板输注,21%使用血小板生成素受体激动剂,13%接受静脉免疫球蛋白,8%接受CD34+干细胞 boost。
  • 第100天时,19%和13%患者分别持续使用血小板生成素受体激动剂和粒细胞集落刺激因子。
  • 感染发生率为54%,其中23%为≥3级;第30天内早期感染68%为细菌性、50%为严重,第31至100天感染50%为细菌性、42%为病毒性、仅13%为≥3级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines of therapy. On the KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize cytopenias and infections within 100 days after ide-cel in the standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data were censored at day 100. Grade ≥ 3 cytopenia was present among 65% of patients at day 30 and 40% of patients at day 90. Granulocyte colony stimulating factor (G-CSF) was administered to 88%, packed red blood cell transfusions to 63%, platelet transfusions to 42%, thrombopoietin (TPO) agonists to 21%, intravenous immunoglobulin to 13%, and CD34+ stem cell boosts to 8%. At day 100, 19% and 13% of patients had ongoing use of TPO agonists and G-CSF, respectively. Infections occurred in 54% of patients and were grade ≥ 3 in 23%. Earlier infections in the first 30 days were typically bacterial (68%) and severe (50%). Later infections between days 31 and 100 were 50% bacterial and 42% viral; only 13% were grade ≥ 3. On univariate analysis, high pre-CAR-T marrow myeloma burden (≥ 50%), circulating plasma cells at pre-lymphodepletion (LD), and grade ≥ 3 anemia at pre-LD were associated with grade ≥ 3 cytopenia at both days 30 and 90. Longer time from last bridging treatment to LD was the only significant risk factor for infection.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Logue JM, Peres LC, Hashmi H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022. PMID: 35939783. doi:10.1182/bloodadvances.2022008320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。